Overview
James Ip, MD, FACC, FHRS was born and raised in New York City. After graduating summa cum laude from Columbia University, he attended Harvard Medical School. There, he received a Doris Duke Clinical Research Fellowship, which enabled him to pursue research interests in cardiovascular genetics and stem cell therapy. He completed his internal medicine residency at the Brigham and Women's Hospital in Boston and returned to New York for his cardiovascular disease and cardiac electrophysiology fellowships at Cornell University Medical Center. He has now joined the team of electrophysiologists at Cornell as a full-time faculty member.
Highlights
- 1
- 2
- 3
Publications
Clinical research
Active
5 studies- PINCT06716021Multi-Center, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients With Atrial Fibrillation and Rapid Ventricular Rate (RVR)PHASE3 · Milestone Pharmaceuticals · OPEN TO ACCRUAL (as of 2026)Atrial Fibrillation
- PINCT07118358BIOTRONIK Investigation of the LivIQ Leadless Pacemaker SystemNA · BIOTRONIK, Inc. · OPEN TO ACCRUAL (as of 2026)Leadless Pacemaker; Bradycardia; AV Block; Cardiac Rhythm Disorder
- PINCT07098858The WiSE®-UP Study (The WiSE System Utilization & Performance Study)EBR Systems, Inc · OPEN TO ACCRUAL (as of 2025)Heart Failure
- PIOutcomes of Cardiac Implantable Electronic Device PatientsWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIBiobank for Atrial Fibrillation and ArrhythmiasWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2024)
Completed & closed trials (11)
- PINCT04952610An Open Label Extension Study of Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular TachycardiaPHASE3 · Milestone Pharmaceuticals · IRB STUDY CLOSURE (as of 2026)Paroxysmal Supraventricular Tachycardia
- PINCT05855135Assessment of the Safety and Efficacy of a Combined Cardiac Contractility Modulation and Implantable Cardioverter Defibrillator Device for Subjects With Heart Failure and Reduced Ejection FractionNA · Impulse Dynamics USA, Inc. · CLOSED TO ACCRUAL (as of 2025)Heart Failure; Heart Failure With Reduced Ejection Fraction; Implantable Defibrillator User; CCM Therapy; Non-ischemic Cardiomyopathy; Ischemic Cardiomyopathy; Sudden Cardiac Arrest; Arrhythmias, Cardiac; Ventricular Tachycardia; Ventricular Fibrillation
- PINCT01816776A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep ApneaNA · Respicardia, Inc · IRB STUDY CLOSURE (as of 2025)Sleep Apnea, Central; Sleep Disordered Breathing; Heart Failure
- PINCT05064709Assessment of Implantable CCM in the Heart Failure Group With Higher Ejection FractionNA · Impulse Dynamics USA, Inc. · IRB STUDY CLOSURE (as of 2025)Heart Failure; Heart Failure With Preserved Ejection Fraction; Heart Failure With Mid Range Ejection Fraction; Heart Failure With Moderately Reduced Ejection Fraction; Diastolic Heart Failure
- PINCT04559945The LEADLESS II IDE Study (Phase II): A Safety and Effectiveness Trial for a Leadless Pacemaker SystemNA · Abbott Cardiovascular Systems, Inc. · IRB STUDY CLOSURE (as of 2023)Cardiac Rhythm Disorder; Bradycardia
- PINCT05356546TYRX™ Pocket Health StudyMedtronic Vascular, Inc. · IRB STUDY CLOSURE (as of 2023)Cardiac Disease; Healing Surgical Wounds
- PINCT05039359A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus RhythmPHASE3 · InCarda Therapeutics · IRB STUDY CLOSURE (as of 2023)Paroxysmal Atrial Fibrillation
- PINCT03464019Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. NODE 301 and RAPID StudiesPHASE3 · Milestone Pharmaceuticals · IRB STUDY CLOSURE (as of 2023)Paroxysmal Supraventricular Tachycardia
- PINCT04072835The NODE-303 Study: Multi-Centre, Multi-National,Open Label, Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia.PHASE3 · Milestone Pharmaceuticals · IRB STUDY CLOSURE (as of 2023)Paroxysmal Supraventricular Tachycardia
- PINCT02030418The LEADLESS II IDE Study (Phase I): Safety and Effectiveness Trial for the Nanostim Leadless PacemakerNA · St. Jude Medical Foundation · IRB STUDY CLOSURE (as of 2022)Bradycardia
- PINCT03539302A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial FibrillationPHASE2 · InCarda Therapeutics · IRB STUDY CLOSURE (as of 2021)Paroxysmal Atrial Fibrillation (PAF)
Available technologies
News mentions
- Study Finds Lasting, Reliable Performance for Wireless PacemakerJuly 30, 2024
A dual-chamber wireless pacemaker provides reliable performance over three months, bolstering evidence for this new pacemaker option, according to results from a multi-center, international clinical trial co-led by a Weill Cornell Medicine and NewYork-Presbyterian investigator.
- Clinical Trial Finds Nasal Spray Safely Treats Recurrent Abnormal Heart RhythmsApril 9, 2024
A clinical trial led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician, successfully and safely treated recurrent episodes of a condition that causes rapid abnormal heart rhythms.
Media highlights
- New Data Demonstrate Etripamil Nasal Spray Can Convert Recurrent PSVT To Normal Heart Rhythm In Prior-Ablation PatientsCardiac Rhythm News · November 4, 2026
External relationships
Advisory/Scientific Board Member
Abbott Cardiovascular Systems, Inc. · Medtronic, Inc.
Professional Services
Abbott Cardiovascular Systems, Inc. · Boston Scientific Corporation
Other
Abbott Cardiovascular Systems, Inc.